Neurocrine biosciences announces initiation of phase 1 clinical study evaluating nbip-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist

San diego , june 30, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the initiation of a phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound nbip-01435 in healthy adult participants. nbip-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (cah).
NBIX Ratings Summary
NBIX Quant Ranking